Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

XRP Price: XRP Just Broke Below $1.35 — Will the $1.28 Support Hold?

View original at finance.yahoo.com
XRP Price: XRP Just Broke Below $1.35 — Will the $1.28 Support Hold? Quick Read XRP broke below $1.35 on March 28 after Bitcoin dropped to $66,000 and $14.16 billion in quarterly options expired on Deribit, ending a support level that had held through most of March…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Each bounce at $1.35 came on lower volume than the one before—a clear sign that the demand holding the level together was thinning out

    60% confidence

  • How XRP reacts at $1.28 could shape the next few weeks of price action

    60% confidence

  • The $1.28 support is the 23.6% Fibonacci bear market floor with 443 million XRP in accumulated cost basis

    60% confidence

  • Below $1.28 there's very little support until $1.11

    60% confidence

Data points we hold from this source

XRP · accumulated cost basis443 million_XRP
XRP · support level1.35 USD
XRP · rsi41 index
XRP · low price1.12 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
XRP Price: XRP Just Broke Below $1.35 — Will the $1.28 Support Hold? — Source | Via News | ViaNews Market